Results 101 to 110 of about 10,879 (228)

Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study [PDF]

, 2018
AIM: To evaluate waiting list (WL) registration and liver transplantation (LT) rates in patients with hepatitis C virus (HCV)-related cirrhosis since the introduction of direct-acting antivirals (DAAs).
Angeli, Paolo, Burra, Patrizia, Cillo, Umberto, Ferrarese, Alberto, Gambato, Martina, Germani, Giacomo, Russo, Francesco Paolo, Senzolo, Marco, Shalaby, Sarah, Zanetto, Alberto, Zanus, Giacomo   +10 more
core   +1 more source

Safety and Efficacy of Ledipasvir–Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6‐11

Hepatology, 2018
Currently, there are no interferon‐free treatments available for hepatitis C virus (HCV)–infected patients younger than 12 years. We evaluated the safety and effectiveness of the all‐oral regimen ledipasvir–sofosbuvir ± ribavirin in HCV‐infected children
K. Murray, W. Balistreri, S. Bansal, S. Whitworth, H. Evans, R. Gonzalez-Peralta, Jessica W. Wen, B. Massetto, K. Kersey, J. Shao, K. Garrison, Bandita Parhy, D. Brainard, R. Arnon, L. Gillis, M. Jonas, Chuan-Hao Lin, M. Narkewicz, K. Schwarz, P. Rosenthal   +19 more
semanticscholar   +1 more source

Changes in serum myostatin levels among patients with type C liver cirrhosis treated with direct‐acting antivirals

Hepatology Research, Volume 55, Issue 5, Page 631-637, May 2025.
Direct‐acting antiviral treatment for patients with type C liver cirrhosis not only improves the liver function, but also reduces the myostatin level, which is associated with muscle atrophy. Therefore, antiviral therapy may improve sarcopenia associated with chronic liver disease.
Tomoyuki Suehiro, Hideko Kozuru, Kosuke Matusmoto, Yuki Kugiyama, Yasuhide Motoyoshi, Akira Saeki, Shinya Nagaoka, Kazumi Yamasaki, Atsumasa Komori, Hiroshi Yatsuhashi   +9 more
wiley   +1 more source

Combination ledipasvir-sofosbuvir for the treatment of chronic hepatitis C virus infection: a review and clinical perspective

Therapeutics and Clinical Risk Management, 2016
Marcel Nkuize,1 Thomas Sersté,1,2 Michel Buset,1 Jean-Pierre Mulkay11Department of Gastroenterology and Hepatology, Saint-Pierre University Hospital, 2Department of Gastroenterology, Pancreatology and Hepatology, Hôpital Academique Erasme ...
Nkuize M, Sersté T, Buset M, Mulkay JP
doaj  

Metabolic syndrome does not affect sustained virologic response of direct-acting antivirals while hepatitis C clearance improves hemoglobin A1c. [PDF]

, 2018
AimTo determine whether successful treatment with directacting antivirals (DAA) is associated with improvements in hemoglobin A1c (HbA1c) and if type 2 diabetes mellitus (T2DM) or metabolic syndrome affects sustained virologic response (SVR).MethodsWe ...
Aby, Elizabeth S, Benhammou, Jihane N, Dong, Tien S, Han, Steven-Huy, Kawamoto, Jenna, May, Folasade P, Pisegna, Joseph R   +6 more
core  

Direct‐Acting Antiviral Treatment Failure and Retreatment Strategies Following Hepatitis C‐Positive Solid Organ Transplantation in Hepatitis C‐Negative Recipients: A Multicenter Case Series

Transplant Infectious Disease, Volume 27, Issue 3, May/June 2025.
A multicenter, retrospective case series describes the population of hepatitis C virus (HCV) donor+/ recipient− (D+/R−) solid organ transplant (SOT) recipients failing an initial direct‐acting antiviral (DAA). Retreatment strategies and subsequent sustained virologic response (SVR) rates are reported.
Alicia B. Carver, Claire Özoral, Morgan Lange, Alysa Mattise, Kristen Whelchel, Roman Perri   +5 more
wiley   +1 more source

Thrombospondin 2 as a Predictive Biomarker for HCC in Hepatitis C Patients: A Longitudinal Study Following DAA Therapy

Journal of Viral Hepatitis, Volume 32, Issue 4, April 2025.
ABSTRACT This multicentre study investigated the dynamics of thrombospondin 2 (TSP2) levels during direct‐acting antiviral (DAA) therapy in hepatitis C virus (HCV) infected patients and evaluated TSP2's potential as a predictive marker for hepatocellular carcinoma (HCC).
Takanobu Iwadare, Takefumi Kimura, Ayumi Sugiura, Taiki Okumura, Shun‐ichi Wakabayashi, Hiroyuki Kobayashi, Yuki Yamashita, Tomoo Yamazaki, Satoru Joshita, Naoki Tanaka, Takeji Umemura   +10 more
wiley   +1 more source

Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service

ClinicoEconomics and Outcomes Research, 2017
Kirsten Y Westerhout,1 Walter Bouwmeester,1 Inge Duchesne,2 Marta Pisini,2 Marjanne A Piena,1 Francesco Damele,3 Beatrice Gueron,2 Maarten Treur,1 Jonathan Belsey4 1Pharmerit BV, Marten Meesweg, Rotterdam, the Netherlands; 2Janssen EMEA, Turnhoutseweg ...
Westerhout KY, Bouwmeester W, Duchesne I, Pisini M, Piena MA, Damele F, Gueron B, Treur M, Belsey J   +8 more
doaj  

Increased Eligibility for Treatment of Chronic Hepatitis C Infection with Shortened Duration of Therapy: Implications for Access to Care and Elimination Strategies in Canada

Canadian Journal of Gastroenterology and Hepatology, 2015
BACKGROUND: All oral, highly effective direct-acting antiviral combinations, such as sofosbuvir-ledipasvir, have recently been licensed in Canada but cost as much as $67,000 for a 12-week course of therapy, representing a major economic barrier to ...
Sergio M Borgia, Adenike Rowaiye
doaj   +1 more source

Hepatitis C in Special Patient Cohorts: New Opportunities in Decompensated Liver Cirrhosis, End-Stage Renal Disease and Transplant Medicine

, 2015
Worldwide, hepatitis C virus (HCV) is a common infection. Due to new antiviral approaches and the approval of direct-acting antiviral agents (DAA), HCV therapy has become more comfortable. Nevertheless, there are special patient groups, in whom treatment
Heinzow, H. (Hauke), Hüsing, A.K.E.P. (Anna), Kabar, I. (Iyad), Schmidt, H. (Hartmut)   +3 more
core   +2 more sources